- Promising results from the EMAGINE randomized trial show that BRAIN.Q's AI-powered low-electromagnetic field stimulation treatment, aimed at strengthening the brain's ability to relearn processes lost after a stroke, helped patients “recover from disability.” This suggests that it may have a higher probability of helping people regain their “liberation.''
- First use of wearable, cloud-connected treatment system from moderate This demonstrates the feasibility of autonomous use at home by patients and their caregivers and a very high safety profile.
- The new technology has received FDA Breakthrough Device designation, and the company expects to receive the CE mark next year.
- The results of the clinical trial were announced by Dr. Jeffrey SaberStroke Director University of California Los Angelespresented as Latest Science at the European Stroke Congress (ESOC) plenary session.
Jerusalem, May 16, 2024 /PRNewswire/ — Brain QAI-driven emerging leaders Brain Llongevity THerapeutics today announced encouraging results from EMAGINE, a U.S. multicenter randomized controlled study. This suggests that the company's AI-powered electromagnetic field therapy treatments may lead to meaningful clinical benefits and significant reductions in post-stroke disability. These promising results are in line with encouraging findings observed in an initial randomized controlled pilot study conducted with the BRAIN.Q therapy, published in 2021.
BRAIN.Q's next generation Q therapy system (PRNewsfoto/BrainQ)
The trial, conducted at 15 major academic centers in the United States, showed that brain stimulation therapy included: from moderate It was targeted at patients with severe ischemic stroke and was conducted as a daily session in the weeks following the stroke.Although not reaching statistical significance, the results suggested that treated patients were likely to have greater reductions in disability levels after stroke compared with patients with in of Control group.
The findings suggest that patients who were actively treated were more than twice as likely to be disability-free after three months. This means returning to independent living and returning to work, social activities, and hobbies.
Promising results were announced today by Drs. Jeffrey L. SaberStroke Director University of California Los Angeles National co-investigator of the EMAGINE study as late-stage breakthrough science at the European Stroke Conference (ESOC). “Over the past several decades, we have made tremendous progress in emergency stroke treatment that reduces but does not completely prevent brain damage,” Dr. Saber says. The debilitating disability caused by stroke remains common, but the welcome results of this study suggest that even severe stroke patients may be able to get relief from their disability with this treatment. ” In this trial, brain stimulation therapy also showed an excellent safety profile, with a limited number of adverse events and no serious treatment-related adverse events. BRAIN.Q relies on emerging science that suggests the use of targeted stimulation of brain network activity as the key to maximizing the brain's learning capacity. The company uses his AI to analyze data sets of brain network activity and mirrors it back to patients to maximize recovery.
This is also the first use of a wearable, cloud-connected treatment system for severely disabled stroke patients, designed to address a patient's fragmented path from hospital to home. The company reports impressive patient compliance rates of approximately 90%, with more than 2,500 sessions successfully conducted autonomously and at home by patients and their caregivers.
“Millions of stroke survivors around the world endure life-altering disabilities. The results of the EMAGINE trial could lead to treatments that can help these patients reclaim their lives from the comfort of their own homes. “This represents a major step forward,” he said. yotam drexlerRepresentative director of BRAIN.Q.
The company plans to launch a pivotal trial version of its next-generation technology, EMAGINE 2.0, in the U.S. this summer and expects to receive CE mark approval later this year.
About BRAIN.Q: The company, a privately held U.S. and Israel-based startup and emerging leader in AI-powered brain longevity treatments, is dedicated to developing innovative solutions that change the lives of patients suffering from neurological disorders. The company has received breakthrough device designation from the FDA. For more information, please visit: https://brainqtech.com/.
Press contact:
Leah Stern
Partner, Global Communications @OurCrowd
England: +44-747-019-6826
US: +1-646-568-9916
Israel: +972-2-560-9486
E: [email protected]
Photo – https://mma.prnewswire.com/media/2415039/BrainQ.jpg
Source BrainQ
